Greenwich LifeSciences (GLSI) Net Income towards Common Stockholders (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Net Income towards Common Stockholders of -$17.2 million for Q4 2025, down 314.23% on a QoQ basis from -$4.2 million in Q3 2025, and down 5.48% year-over-year from -$18.2 million in Q4 2024.
Greenwich LifeSciences (GLSI) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$17.2 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 5.48% year-over-year to -$17.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$28.6 million (down 19.04% YoY) and the FY2025 annual result came in at -$28.6 million, down 19.04% from the prior year.
- Net Income towards Common Stockholders was -$17.2 million for Q4 2025 at Greenwich LifeSciences, down from -$4.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$597008.0 in Q1 2021 and bottomed at -$17.2 million in Q4 2025.
- A 5-year average of -$4.2 million and a median of -$2.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders slumped 256.29% — and 2022, when it gained 0.49%.
- Greenwich LifeSciences' Net Income towards Common Stockholders stood at -$3.9 million in 2021, then tumbled by 52.98% to -$5.9 million in 2022, then decreased by 22.34% to -$7.3 million in 2023, then plunged by 124.83% to -$16.3 million in 2024, then decreased by 5.48% to -$17.2 million in 2025.
- Business Quant data shows GLSI's Net Income towards Common Stockholders at -$17.2 million in Q4 2025, -$4.2 million in Q3 2025, and -$4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Greenwich LifeSciences | 183.67 Mn | 183.67 Mn | - | -17.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.20 Mn |
| Sep 30, 2025 | -4.15 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | -3.26 Mn |
| Dec 31, 2024 | -16.30 Mn |
| Sep 30, 2024 | -2.67 Mn |
| Jun 30, 2024 | -2.61 Mn |
| Mar 31, 2024 | -2.47 Mn |
| Dec 31, 2023 | -7.25 Mn |
| Sep 30, 2023 | -2.39 Mn |
| Jun 30, 2023 | -1.63 Mn |
| Mar 31, 2023 | -2.12 Mn |
| Dec 31, 2022 | -5.93 Mn |
| Sep 30, 2022 | -2.32 Mn |
| Jun 30, 2022 | -746,073.00 |
| Mar 31, 2022 | -1.97 Mn |
| Dec 31, 2021 | -3.87 Mn |
| Sep 30, 2021 | -863,118.00 |
| Jun 30, 2021 | -749,745.00 |
| Mar 31, 2021 | -597,008.00 |